Recent studies have provided evidence for using magnetic resonance imaging (MRI) active lesions as surrogate for relapses and disability progression in multiple sclerosis (MS). However, the validity of MRI metrics as surrogate endpoints in MS is controversial. Furthermore, the extrapolation of previous results to novel therapies is not warranted. We tested here the validity of MRI surrogacy in MS studies on recently published trials of oral drugs. The 92% of observed effects of oral drugs on clinical outcomes resulted close to those predicted by MRI active lesions. This further validates MRI surrogacy in MS, with important implications for future trials planning.
SormaniMPFilippiMDe StefanoNEbersGDaumerM. MRI as an outcome in multiple sclerosis clinical trials. Neurology2009; 73: 1932–1933.
2.
DaumerMNeuhausAMorrisseySHintzenREbersGC. MRI as an outcome in multiple sclerosis clinical trials. Neurology2009; 72: 705–711.
3.
KapposLRadueEWO'ConnorP. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med2010; 362: 387–401.
4.
GiovannoniGComiGCookS. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med2010; 362: 416–426.
5.
CohenJABarkhofFComiG. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med2010; 362: 402–415.
6.
SormaniMPBonzanoLRoccatagliataL. Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: a meta-analytic approach. Ann Neurol2009; 65: 268–275.
7.
Sormani MP, Bonzano L, Roccatagliata L, et al. Surrogate endpoints for EDSS worsening in multiple sclerosis: a meta-analytic approach. Neurology Epub 2010 Jun 23.
8.
Giovannoni G, Comi G, Cook S, et al. Clinical efficacy of cladribine tablet therapy in patients with relapsing-remitting multiple sclerosis (RRMS): results from the CLARITY study, a 96-week, phase III, double-blind, placebo-controlled trial. 19th European Neurological Society Meeting. Milan, Italy, 2009.
9.
Comi G, Cook S, Giovannoni G, et al. Magnetic resonance imaging (MRI) outcomes in patients with relapsing-remitting multiple sclerosis (RRMS) treated with cladribine tablets: results from the CLARITY study, a 96-week, phase III, double-blind, placebo-controlled trial. 19th European Neurological Society Meeting. Milan, Italy, 2009.
